The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

After years of weight loss drug shortages, the FDA is saying there's now an adequate supply for most medications and they will be prohibiting like-for-like compounded versions.

Oxford Medical Products has announced positive three-month clinical trial results for ... sustained weight loss. People with class 1 obesity lost on average 6.3% of their total body weight. Sirona is ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading. Revenue increased 95% from a year earlier to $481 million ...

GLP-1 drugs, also known as incretin treatments ... developing next-generation treatments with stronger weight-loss effects. Others, like Hims & Hers (HIMS), betted on more affordable off-brand ...

Hims & Hers has bet big on prescribing compounded versions of these drugs, including ... buoyed by the growth of its weight-loss business. Its revenue jumped 69% to $1.48 billion, with its GLP ...